A life sciences startup located in Cambridge, Massachusetts called Vaxess Technologies has secured $12 million to create a shelf-stable MIMIX skin patch for treatments and vaccinations.
Investors
- GHIC
- Mission Bio Capital
- Engine Ventures
- RA Capital Management
- Vaxess now has more than $90 million in total equity and non-dilutive capital.
Use of funds
The money will be used by the business to further develop GLP-1, carry out in vivo mRNA research, and enhance and scale up manufacturing process capabilities in support of new collaborations aimed at delivering next-generation vaccines and treatments.
Rachel Sha has been appointed CEO by Vaxess, with Michael Schrader resigning from his role.
About Vaxess
Under Rachel Sha’s direction, Vaxess offers the MIMIXTM platform, which combines an applicator and unique microarray patch to administer a variety of vaccinations and medicines. The dissolvable microarray tips’ advanced biomaterials allow for high degrees of dosage delivery control and may be altered to deliver various payloads. Furthermore, its MIMIX patch may be sent to low resource settings since it doesn’t need to be refrigerated.
